BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,130 filers reported holding BAXTER INTL INC in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $27,965,500 | -56.5% | 548,665 | -54.1% | 0.42% | -61.3% |
| Q3 2022 | $64,313,000 | -21.2% | 1,194,073 | -6.1% | 1.10% | -12.4% |
| Q2 2022 | $81,653,000 | -12.2% | 1,271,262 | +6.0% | 1.25% | +5.6% |
| Q1 2022 | $92,971,000 | -6.7% | 1,199,013 | +3.2% | 1.19% | +1.5% |
| Q4 2021 | $99,684,000 | +167.9% | 1,161,279 | +151.0% | 1.17% | +153.2% |
| Q3 2021 | $37,206,000 | +7431.6% | 462,580 | +5564.7% | 0.46% | +7600.0% |
| Q2 2017 | $494,000 | +15.2% | 8,166 | -1.3% | 0.01% | +20.0% |
| Q1 2017 | $429,000 | -3.6% | 8,277 | -11.6% | 0.01% | -37.5% |
| Q3 2016 | $445,000 | +9.3% | 9,359 | +4.0% | 0.01% | +14.3% |
| Q2 2016 | $407,000 | +24.8% | 8,997 | +13.3% | 0.01% | +16.7% |
| Q1 2016 | $326,000 | +26.8% | 7,938 | +17.9% | 0.01% | +20.0% |
| Q4 2015 | $257,000 | -19.4% | 6,733 | +55.3% | 0.01% | -28.6% |
| Q1 2014 | $319,000 | +3.6% | 4,336 | -2.0% | 0.01% | 0.0% |
| Q4 2013 | $308,000 | +4.4% | 4,426 | -1.4% | 0.01% | +16.7% |
| Q3 2013 | $295,000 | -6.6% | 4,487 | -1.8% | 0.01% | -14.3% |
| Q2 2013 | $316,000 | – | 4,567 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |